The farnesoid X receptor: A novel drug target?

Expert Opinion on Investigational Drugs

Volumn 13, Issue 9, 2004, Pages 1135-1148

  Claudel, Thierry ^a,b   Sturm, Ekkehard ^b   Kuipers, Folkert ^b   Staels, Bart ^a  

^a INSERM   (France)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bile acid; Cholestasis; FXR; Lipid metabolism; Nuclear receptor

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 4 (2 TETRAHYDRO 5,5,8,8 TETRA METHYL 2 NAPHTHALENYL)1 PROPENYL BENZOIC ACID; 6 ETHYL CHENODEOXYCHOLIC ACID; AGENTS AFFECTING LIPID METABOLISM; AGN 29; AGN 31; AGN 34; BILE ACID; CELL NUCLEUS RECEPTOR; CHENODEOXYCHOLIC ACID; CHENODEOXYCHOLIC ACID DERIVATIVE; CHOLESTEROL; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; FEXARAMINE; ISOXAZOLE DERIVATIVE; TAUROURSODEOXYCHOLIC ACID; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VITAMIN;

BILE ACID METABOLISM; BILE ACID SYNTHESIS; BILE DUCT; CHOLESTASIS; CHOLESTEROL METABOLISM; CONJUGATION; DRUG RESPONSE; DRUG TARGETING; DYSLIPIDEMIA; GENE TARGETING; INTESTINE; LIPID ABSORPTION; LIPID METABOLISM; LIVER LEVEL; NONHUMAN; REVIEW; VITAMIN METABOLISM;

ANIMALS; ANTILIPEMIC AGENTS; BENZENE DERIVATIVES; CHENODEOXYCHOLIC ACID; CHOLESTASIS; DNA-BINDING PROTEINS; HUMANS; HYPERLIPIDEMIAS; MOLECULAR STRUCTURE; OCTANOIC ACIDS; PHENYL ETHERS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 4544339723     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.9.1135     Document Type: Review

References (126)

1. RUSSELL DW: The enzymes, regulation, and genetics of bile acid synthesis. Ann. Rev. Biochem. (2003) 72:137-174.
2. MAKISHIMA M, OKAMOTO AY, REPA JJ et al.: Identification of a nuclear receptor for bile acids. Science (1999) 284(5418):1362-1365.
3. WANG H, CHEN J, HOLLISTER K, SOWERS LC, FORMAN BM: Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell (1999) 3(5):543-553.
4. PARKS DJ, BLANCHARD SG, BLEDSOE RK et al.: Bile acids: natural ligands for an orphan nuclear receptor. Science (1999) 284(5418):1365-1368.
5. LAFFITTE BA, KAST HR, NGUYEN CM et al.: Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J. Biol. Chem. (2000) 275(14):10638-10647.
6. CLAUDEL T, STURM E, DUEZ H et al.: Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. (2002) 109(7):961-971.
7. BARBIER O, TORRA IP, SIRVENT A et al.: FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology (2003) 124(7):1926-1940.
8. ZHANG Y, KAST-WOELBERN HR, EDWARDS PA: Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J. Biol. Chem. (2003) 278(1):104-110.
9. MAGLICH JM, SLUDER A, GUAN X et al.: Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans and Drosophila genomes. Genome Biol. (2001) 2(8):RESEARCH0029
10. OTTE K, KRANZ H, KOBER I et al.: Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol. Cell. Biol. (2003) 23(3):864-872.
11. FORMAN BM, GOODE E, CHEN J et al.: Identification of a nuclear receptor that is activated by farnesol metabolites. Cell (1995) 81(5):687-693.
12. REPA JJ, MANGELSDORF DJ: Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr. Opin. Biotechnol. (1999) 10(6):557-563.
13. CUI J, HEARD TS, YU J et al.: The amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate. J. Biol. Chem. (2002) 277(29):25963-25969.
14. MALONEY PR, PARKS DJ, HAFFNER CD et al.: Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem. (2000) 43(16):2971-2974.
15. GUPTA S, STRAVITZ RT, DENT P, HYLEMON PB: Down-regulation of cholesterol 7α-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J. Biol. Chem. (2001) 276(19):15816-15822.
16. DUSSAULT I, BEARD R, LIN M et al.: Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem. (2003) 278(9):7027-7033.
17. PELLICCIARI R, FIORUCCI S, CAMAIONI E et al.: 6α-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. (2002) 45(17):3569-3572.
18. DOWNES M, VERDECIA MA, ROECKER AJ et al.: A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell (2003) 11(4):1079-1092.
19. MI LZ, DEVARAKONDA S, HARP JM et al.: Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell (2003) 11(4):1093-10100.
20. GROBER J, ZAGHINI I, FUJII H et al.: Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem. (1999) 274(42):29749-29754.
21. KAST HR, NGUYEN CM, SINAL CJ et al.: Farnesoid x-activated receptor induces apolipoprotein c-ii transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. (2001) 15(10):1720-1728.
22. KASSAM A, MIAO B, YOUNG PR, MUKHERJEE R: Retinoid X receptor (RXR) agonist-induced antagonism of farnesoid X receptor (FXR) activity due to absence of coactivator recruitment and decreased DNA binding. J. Biol. Chem. (2003) 278(12):10028-10032.
23. BRAMLETT KS, YAO S, BURRIS TP: Correlation of farnesoid X receptor coactivator recruitment and cholesterol 7α-hydroxylase gene repression by bile acids. Mol. Genet. Metab. (2000) 71(4):609-615.
24. PINEDA TORRA I, FREEDMAN LP, GARABEDIAN MJ: Identification of DRIP205 as a coactivator for the farnesoid X receptor. J. Biol. Chem. (2004)
25. SINAL CJ, TOHKIN M, MIYATA M et al.: Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell (2000) 102(6):731-744.
26. KOK T, HULZEBOS CV, WOLTERS H et al.: Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J. Biol. Chem. (2003) 278(43):41930-41937.
27. CHIANG JY, KIMMEL R, WEINBERGER C, STROUP D: Farnesoid X receptor responds to bile acids and represses cholesterol 7α -hydroxylase gene (CYP7A1) transcription. J. Biol. Chem. (2000) 275(15 ):10918-10924.
28. GOODWIN B, JONES SA, PRICE RR et al.: A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell (2000) 6(3):517-526.
29. LU TT, MAKISHIMA M, REPA JJ et al.: Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell (2000) 6(3):507-515.
30. MIYAKE JH, WANG SL, DAVIS RA: Bile acid induction of cytokine expression by macrophages correlates with repression of hepatic cholesterol 7α-hydroxylase. J. Biol. Chem. (2000) 275(29 ):21805-21808.
31. HOLT JA, LUO G, BILLIN AN et al.: Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. (2003) 17(13):1581-1591.
32. YU C, WANG F, KAN M et al.: Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. (2000) 275(20):15482-15489.
33. EINARSSON K, AKERLUND JE, REIHNER E, BJORKHEM I: 12 α-hydroxylase activity in human liver and its relation to cholesterol 7 α-hydroxylase activity. J. Lipid Res. (1992) 33(11 ):1591-1595.
34. ZHANG M, CHIANG JY: Transcriptional regulation of the human sterol 12α-hydroxylase gene (CYP8B1). Roles of hepatocyte nuclear factor 4α in mediating bile acid repression. J. Biol. Chem. (2001) 276(45):41690-41699.
35. SCHERSTEN T, BJORNTORP P, EKDAHL PH, BJORKERUD S: The synthesis of taurocholic and glycocholic acids by preparations of human liver. II. An analysis of the stimulating effect of the L fraction. Biochim. Biophys. Acta (1967) 141(1):155-163.
36. CZUBA B, VESSEY DA: Purification and characterization of cholyl-CoA: taurine N-acetyltransferase from the liver of domestic fowl (Gallus gallus). Biochem. J. (1981) 195(1):263-266.
37. PIRCHER PC, KITTO JL, PETROWSKI ML et al.: Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. (2003) 278(30):27703-27711.
38. +/bile acid cotransport system. Proc. Natl. Acad. Sci. USA (1991) 88(23):10629-10633.
39. +/bile acid cotransporter. J. Clin. Invest. (1994) 93(3 ):1326-1331.
40. CATTORI V, ECKHARDT U, HAGENBUCH B: Molecular cloning and functional characterization of two alternatively spliced Ntcp isoforms from mouse liver1. Biochim. Biophys. Acta (1999) 1445(1):154-159.
41. +/taurocholate cotransporting polypeptide in rat liver. Gastroenterology (1994) 107(6 ):1781-1787.
42. +)-bile acid cotransporter using peptide and fusion protein antibodies. Am. J. Physiol. (1994) 267(4 Pt 1):G637-643.
43. DENSON LA, STURM E, ECHEVARRIA W et al.: The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, Ntcp. Gastroenterology (2001) 121(1):140-147.
44. ABE T, KAKYO M, TOKUI T et al.: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. (1999) 274(24):17159-17163.
45. HSIANG B, ZHU Y, WANG Z et al.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. (1999) 274(52):37161-37168.
46. KONIG J, CUI Y, NIES AT, KEPPLER D: A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. (2000) 278(1):G156-164.
47. FICKERT P, ZOLLNER G, FUCHSBICHLER A et al.: Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology (2001) 121(1):170-183.
48. AGELLON LB, TORCHIA EC: Intracellular transport of bile acids. Biochim. Biophys. Acta (2000) 1486(1):198-209.
49. ADACHI Y, KAMISAKO T, YAMAMOTO T: The effects of temporary occlusion of the superior mesenteric vein or splenic vein on biliary bilirubin and bile acid excretion in rats. J. Lab. Clin. Med. (1991) 118(3):261-268.
50. MULLER M, ISHIKAWA T, BERGER U et al.: ATP-dependent transport of taurocholate across the hepatocyte canalicular membrane mediated by a 110-kDa glycoprotein binding ATP and bile salt. J. Biol. Chem. (1991) 266(28):18920-18926.
51. NISHIDA T, GATMAITAN Z, CHE M, ARIAS IM: Rat liver canalicular membrane vesicles contain an ATP-dependent bile acid transport system. Proc. Natl. Acad. Sci. USA (1991) 88(15):6590-6594.
52. GERLOFF T, STIEGER B, HAGENBUCH B et al.: The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. (1998) 273(16):10046-10050.
53. GREEN RM, HODA F, WARD KL: Molecular cloning and characterization of the murine bile salt export pump. Gene (2000) 241(1):117-123.
54. JANSEN PL, STRAUTNIEKS SS, JACQUEMIN E et al.: Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology (1999) 117(6):1370-1379.
55. WANG R, SALEM M, YOUSEF IM et al.: Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc. Natl. Acad. Sci. USA (2001) 98(4):2011-2016.
56. ANANTHANARAYANAN M, BALASUBRAMANIAN N, MAKISHIMA M, MANGELSDORF DJ, SUCHY FJ: Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. (2001) 276(31):28857-28865.
57. PLASS JR, MOL O, HEEGSMA J et al.: Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology (2002) 35(3):589-596.
58. LAZARIDIS KN, PHAM L, TIETZ P et al.: Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J. Clin. Invest. (1997) 100(11):2714-2721.
59. LAZARIDIS KN, TIETZ P, WU T et al.: Alternative splicing of the rat sodium/bile acid transporter changes its cellular localization and transport properties. Proc. Natl. Acad. Sci. USA (2000) 97(20):11092-11097.
60. KOOL M, VAN DER LINDEN M, DE HAAS M et al.: MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA (1999) 96(12):6914-6919.
61. SOROKA CJ, LEE JM, AZZAROLI F, BOYER JL: Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology (2001) 33(4):783-791.
62. WONG MH, OELKERS P, CRADDOCK AL, DAWSON PA: Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter. J. Biol. Chem. (1994) 269(2):1340-1347.
63. WONG MH, OELKERS P, DAWSON PA: Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity. J. Biol. Chem. (1995) 270(45):27228-27234.
64. SHNEIDER BL, DAWSON PA, CHRISTIE DM et al.: Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. J. Clin. Invest. (1995) 95(2):745-754.
65. SAEKI T, MATOBA K, FURUKAWA H et al.: Characterization, cDNA cloning, and functional expression of mouse ileal sodium-dependent bile acid transporter. J. Biochem. (Tokyo) (1999) 125(4):846-851.
66. DAWSON PA, HAYWOOD J, CRADDOCK AL et al.: Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J. Biol. Chem. (2003) 278(36):33920-33927.
67. CHEN F, MA L, DAWSON PA et al.: Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J. Biol. Chem. (2003) 278(22):19909-19916.
68. KRAMER W, CORSIERO D, FRIEDRICH M et al.: Intestinal absorption of bile acids: paradoxical behaviour of the 14 kDa ileal lipid-binding protein in differential photoaffinity labelling. Biochem. J. (1998) 333 (Pt 2):335-341.
69. INOKUCHI A, HINOSHITA E, IWAMOTO Y et al.: Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter. J. Biol. Chem. (2001) 276(50):46822-46829.
70. BARNES S, BUCHINA ES, KING RJ, McBURNETT T, TAYLOR KB: Bile acid sulfotransferase I from rat liver sulfates bile acids and 3-hydroxy steroids: purification, N-terminal amino acid sequence, and kinetic properties. J. Lipid Res. (1989) 30(4):529-540.
71. SONG CS, ECHCHGADDA I, BAEK BS et al.: Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid x receptor. J. Biol. Chem. (2001) 276(45):42549-42556.
72. PILLOT T, OUZZINE M, FOURNEL-GIGLEUX S et al.: Glucuronidation of hyodeoxycholic acid in human liver. Evidence for a selective role of UDP-glucuronosyltransferase 2B4. J. Biol. Chem. (1993) 268(34):25636-25642.
73. MONAGHAN G, BURCHELL B, BOXER M: Structure of the human UGT2B4 gene encoding a bile acid UDP-glucuronosyltransferase. Mamm. Genome (1997) 8(9):692-694.
74. MILLER NE, LA VILLE A, CROOK D: Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature (London) (1985) 314(6006):109-111.
75. BARD JM, PARRA HJ, DOUSTE-BLAZY P, FRUCHART JC: Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism (1990) 39(3):269-273.
76. HAGEN E, ISTAD H, OSE L et al.: Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. Eur. J. Clin. Pharmacol. (1994) 46(5):445-449.
77. LEISS O, VON BERGMANN K: Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. Scand. J. Gastroenterol. (1982) 17(5):587-592.
78. KURIYAMA M, TOKIMURA Y, FUJIYAMA J, UTATSU Y, OSAME M: Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. J. Neurol. Sci (1994) 125(1):22-28.
79. URIZAR NL, DOWHAN DH, MOORE DD: The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J. Biol. Chem. (2000) 275(50):39313-39317.
80. MOLGAARD J, VON SCHENCK H, OLSSON AG: Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia. Eur. J. Clin. Pharmacol. (1989) 36(5):455-460.
81. BUCHWALD H, VARCO RL, MATTS JP et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl. J. Med. (1990) 323(14):946-955.
82. REPA JJ, LUND EG, HORTON JD et al.: Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid feeding. J. Biol. Chem. (2000) 275(50):39685-39692.
83. CLAUDEL T, INOUE Y, BARBIER O et al.: Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology (2003) 125(2):544-555.
84. PENNACCHIO LA, OLIVIER M, HUBACEK JA et al.: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science (2001) 294(5540):169-173.
85. PRIEUR X, COSTE H, RODRIGUEZ JC: The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-α and contains a novel farnesoid X-activated receptor response element. J. Biol. Chem. (2003) 278(28):25468-25480.
86. WILLIAMS KJ, FLESS GM, PETRIE KA et al.: Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J. Biol. Chem. (1992) 267(19):13284-13292.
87. ANISFELD AM, KAST-WOELBERN HR, MEYER ME et al.: Syndecan-1 expression is regulated in an isoform specific manner by the farnesoid-X receptor. J. Biol. Chem. (2003) 26:26.
88. WILLSON TM, BROWN PJ, STERNBACH DD, HENKE BR: The PPARs: from orphan receptors to drug discovery. J. Med. Chem. (2000) 43(4):527-550.
89. STAELS B, DALLONGEVILLE J, AUWERX J et al.: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 98(19):2088-2093.
90. PATEL DD, KNIGHT BL, SOUTAR AK, GIBBONS GF, WADE DP: The effect of peroxisome-proliferator-activated receptor-α on the activity of the cholesterol 7 α-hydroxylase gene. Biochem. J. (2000) 351 (Pt 3):747-753.
91. POST SM, DUEZ H, GERVOIS PP et al.: Fibrates suppress bile acid synthesis via peroxisome proliferator- activated receptor-α-mediated downregulation of cholesterol 7α -hydroxylase and sterol 27-hydroxylase expression. Arterioscler. Thromb. Vasc. Biol. (2001) 21(11):1840-1845.
92. PINEDA TORRA I, CLAUDEL T, DUVAL C et al.: Bile acids induce the expression of the human peroxisome proliferator- activated receptor-α gene via activation of the farnesoid X receptor. Mol. Endocrinol. (2003) 17(2):259-272.
93. ZHANG Y, CASTELLANI LW, SINAL CJ, GONZALEZ FJ, EDWARDS PA: Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. (2004) 18(2):157-169.
94. JANSEN PL, MULLER M, STURM E: Genes and cholestasis. Hepatology (2001) 34(6):1067-1074.
95. SHNEIDER BL, FOX VL, SCHWARZ KB et al.: Hepatic basolateral sodium-dependent-bile acid transporter expression in two unusual cases of hypercholanemia and in extrahepatic biliary atresia. Hepatology (1997) 25(5):1176-1183.
96. ZOLLNER G, FICKERT P, ZENZ R et al.: Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology (2001) 33(3):633-646.
97. RIUS M, NIES AT, HUMMEL-EISENBEISS J, JEDLITSCHKY G, KEPPLER D: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology (2003) 38(2):374-384.
98. ZOLLNER G, FICKERT P, FUCHSBICHLER A et al.: Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J. Hepatol. (2003) 39(4):480-488.
99. PAUMGARTNER G, BEUERS U: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology (2002) 36(3):525-531.
100. LEW JL, ZHAO A, YU J et al.: The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J. Biol. Chem. (2004) 279(10):8856-8861.
101. TRAUNER M, MEIER PJ, BOYER JL: Molecular pathogenesis of cholestasis. N. Engl. J. Med. (1998) 339(17):1217-1227.
102. PUNTIS MC, JIANG WG: Plasma cytokine levels and monocyte activation in patients with obstructive jaundice. J. Gastroenterol. Hepatol. (1996) 11(1):7-13.
103. BEMELMANS MH, GOUMA DJ, GREVE JW, BUURMAN WA: Cytokines tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology (1992) 15(6):1132-1136.
104. PLEBANI M, PANOZZO MP, BASSO D et al.: Cytokines and the progression of liver damage in experimental bile duct ligation. Clin. Exp. Pharmacol. Physiol. (1999) 26(4):358-363.
105. LIU Y, BINZ J, NUMERICK MJ et al.: Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. (2003)
106. WAGNER M, FICKERT P, ZOLLNER G et al.: Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 125(3):825-838.
107. CHISHOLM JW, DOLPHIN PJ: Abnormal lipoproteins in the ANIT-treated rat: a transient and reversible animal model of intrahepatic cholestasis. J. Lipid Res. (1996) 37(5):1086-1098.
108. ORSLER DJ, AHMED-CHOUDHURY J, CHIPMAN JK, HAMMOND T, COLEMAN R: ANIT-induced disruption of biliary function in rat hepatocyte couplets. Toxicol. Sci. (1999) 47(2):203-210.
109. GOULIS J, LEANDRO G, BURROUGHS AK: Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet (1999) 354(9184):1053-1060.
110. CLAYTON PT, MILLS KA, JOHNSON AW, BARABINO A, MARAZZI MG: δ4-3-oxosteroid 5 β-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. Gut (1996) 38(4):623-628.
111. ICHIMIYA H, EGESTAD B, NAZER H et al.: Bile acids and bile alcohols in a child with hepatic 3 β-hydroxy-δ 5-C27-steroid dehydrogenase deficiency: effects of chenodeoxycholic acid treatment. J. Lipid Res. (1991) 32(5):829-841.
112. ICHIMIYA H, NAZER H, GUNASEKARAN T, CLAYTON P, SJOVALL J: Treatment of chronic liver disease caused by 3 β-hydroxy-δ 5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid. Arch. Dis. Child. (1990) 65(10):1121-1124.
113. GULDUTUNA S, LEUSCHNER M, WUNDERLICH N et al.: Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function. Eur. J. Clin. Pharmacol. (1993) 45(3):221-225.
114. MILLER GJ, MILLER NE: Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet (1975) 1(7897):16-19.
115. GORDON T, CASTELLI WP, HJORTLAND MC, KANNEL WB, DAWBER TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. (1977) 62(5):707-714.
116. RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. (1999) 341(6):410-418.
117. AUSTIN MA: Plasma triglyceride and coronary heart disease. Arterioscler. Thromb. (1991) 11(1):2-14.
118. ASSMANN G, SCHULTE H, FUNKE H, VON ECKARDSTEIN A: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur. Heart J. (1998) 19(Suppl. M):M8-M14.
119. HODIS HN: Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation (1999) 99(22):2852-2854.
120. SACKS FM, ALAUPOVIC P, MOYE LA et al.: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 102(16):1886-1892.
121. DEV S: Ethnotherapeutics and modern drug development the potential of Ayurveda. Curr. Sci. (1997) 73:909-928.
122. SATYAVATI GV, DWARAKANATH C, TRIPATHI SN: Experimental studies on the hypocholesterolemic effect of Commiphora mukul. Engl. (Guggul). Indian J. Med. Res. (1969) 57(10):1950-1962.
123. NITYANAND S, KAPOOR NK: Cholesterol lowering activity of the various fractions of guggul, Indian J. Exp. Biol. (1973) 11:395-398.
124. URIZAR NL, LIVERMAN AB, DODDS DT et al.: A natural product that lowers cholesterol as an antagonist ligand for FXR. Science (2002) 296(5573):1703-1706.
125. CUI J, HUANG L, ZHAO A et al.: Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. (2003) 278(12):10214-10220.
126. SZAPARY PO, WOLFE ML, BLOEDON LT et al.: Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA (2003) 290(6):765-772.